Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04477200
Recruitment Status : Recruiting
First Posted : July 20, 2020
Last Update Posted : January 26, 2022
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Michigan Rogel Cancer Center

Brief Summary:
This is a phase 0/1 dose-escalation trial to determine the maximum tolerated dose of Mycophenolate Mofetil (MMF) when administered with radiation, in patients with glioblastoma or gliosarcoma.

Condition or disease Intervention/treatment Phase
Glioblastoma Gliosarcoma Drug: Mycophenolate Mofetil Radiation: Radiation Therapy Procedure: Re-resection (as part of standard of care) Drug: Temozolomide Phase 1

Detailed Description:
The goal of the Phase 0 component is to determine if MMF achieves active concentrations in brain tumors. Eight participants in Phase 0 will receive MMF for one week before undergoing an already planned biopsy or re-resection (surgical removal) of glioblastoma or gliosarcoma (GBM/GS). A small portion of the tumor, removed as part of clinical care, will be used for testing in this study. Sixty additional participants will be enrolled in the Phase 1 component of the trial (30 with recurrent GBM/GS and 30 with newly diagnosed GBM/GS). The goal of the Phase 1 component is to find the dose of MMF that works best without causing severe side effects (the maximum tolerated dose) when combined with radiation in recurrent GBM/GS and with radiation and chemotherapy in newly diagnosed GBM/GS. Participants in Phase 0 who meet the eligibility criteria for the Phase 1 component may participate in both phases.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 68 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Phase 0 will include 8 participants; eligible participants from phase 0 may continue on to phase 1.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 0/I Dose Escalation Study of Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma
Actual Study Start Date : August 5, 2020
Estimated Primary Completion Date : October 2024
Estimated Study Completion Date : October 2027


Arm Intervention/treatment
Experimental: Phase 0 - Recurrent glioblastoma (GBM) / gliosarcoma (GS)
Mycophenolate mofetil
Drug: Mycophenolate Mofetil
500-2000mg orally twice daily, one week prior to re-resection (2 participants at each of 4 dose levels: 500mg, 1000mg, 1500mg and 2000mg)
Other Name: MMF

Procedure: Re-resection (as part of standard of care)
Re-resection or biopsy of tumor as part of standard of care

Experimental: Phase 1 - Recurrent GBM / GS
Mycophenolate mofetil; radiation therapy
Radiation: Radiation Therapy
40.5 Gy in 15 fractions
Other Name: RT

Drug: Mycophenolate Mofetil
250-2000mg orally twice daily, one week prior to and concurrent with RT.
Other Name: MMF

Experimental: Phase 1 - Newly Diagnosed GBM / GS
Mycophenolate mofetil; radiation therapy; temozolomide
Drug: Temozolomide
Temozolomide capsules are an approved oral chemotherapeutic drug for the treatment of adult patients with newly diagnosed GBM/GS concomitantly with radiotherapy and then as adjuvant treatment. The dosing and timing of temozolomide therapy will be determined as per standard-of-care for the individual patient by the treating oncologist.
Other Name: TMZ

Drug: Mycophenolate Mofetil
250-2000mg orally twice daily, one week prior to and concurrent with RT and cyclic chemotherapy with temozolomide.
Other Name: MMF

Radiation: Radiation Therapy
60 Gy in 30 fractions
Other Name: RT




Primary Outcome Measures :
  1. Concentration of mycophenolic acid (MPA) in tumor tissue in Phase 0 participants [ Time Frame: At 1 week ]

    The concentration of MPA (the active metabolite of mycophenolate mofetil [MMF]) in tumor tissue, measured by mass spectrometry on a continuous scale after one week of MMF administration.

    This measure includes all phase 0 participants.


  2. Number of recurrent phase 1 participants who experience dose-limiting toxicities (DLTs) at each dose level [ Time Frame: Up to 28 days following completion of MMF + RT (up to ~9 weeks) ]

    DLT will be defined based on the rate of drug related grade 3-5 adverse events experienced from the start of treatment with MMF and for up to 4 weeks after completion of MMF + radiation therapy (RT). Assessed using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.

    This measure includes only phase 1 participants with recurrent GBM/GS.


  3. Number of newly diagnosed phase 1 participants who experience dose-limiting toxicities (DLTs) at each dose level -- DLT1 period [ Time Frame: Up to 28 days following completion of MMF + RT + TMZ (up to ~11 weeks) ]

    DLT will be defined based on the rate of drug related grade 3-5 adverse events experienced from the start of treatment with MMF and for up to 4 weeks after completion of MMF + RT + TMZ. Assessed using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.

    This measure includes only newly diagnosed phase 1 participants.


  4. Number of newly diagnosed phase 1 participants who experience dose-limiting toxicities (DLTs) at each dose level -- DLT2 period [ Time Frame: During the first 2 cycles (8 weeks) of MMF with adjuvant TMZ (up to ~19 weeks) ]

    DLT will be defined based on the rate of drug related grade 3-5 adverse events experienced during the first 2 cycles (8 weeks) of MMF with adjuvant TMZ. (The first cycle of MMF with adjuvant TMZ begins 28 days post-RT.) These will be assessed using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.

    This measure includes only newly diagnosed phase 1 participants.



Secondary Outcome Measures :
  1. Concentrations of guanosine triphosphate (GTP) in tumor tissue in Phase 0 participants [ Time Frame: After one week of MMF administration ]

    The concentrations of GTP in tumor tissue, measured by mass spectrometry on a continuous scale.

    This measure includes all phase 0 participants.


  2. Adverse events associated with treatment in all Phase 1 Participants [ Time Frame: Up to 28 days following completion of MMF + RT (up to ~9 weeks) ]

    Toxicities at each dose level will be tabulated, categorized by grade and attribution.

    This measure includes all phase 1 participants.


  3. Adverse events associated with treatment in newly diagnosed phase 1 participants [ Time Frame: Up to 28 days following completion of MMF with adjuvant temozolomide (up to ~15 months) ]

    Toxicities at each dose level will be tabulated, categorized by grade and attribution.

    This measure includes only newly diagnosed phase 1 participants.


  4. Overall Response Rate in phase 1 participants with recurrent GBM/GS [ Time Frame: Until study stops or death; up to approximately 3 years. ]

    Determined by modified Response Assessment for Neuro-Oncology (mRANO) criteria. The number and proportion of patients with progressive disease, stable disease, partial and complete response will be calculated for each dose level and overall.

    This measure includes only phase 1 participants with recurrent GBM/GS.


  5. Median Progression Free Survival (PFS) in phase 1 participants with recurrent GBM/GS [ Time Frame: Until study stops or death; up to approximately 3 years. ]

    PFS defined as time from date of registration to the date of documented progressive disease, other disease related therapy or death. Determined by mRANO criteria.

    This measure includes only phase 1 participants with recurrent GBM/GS.


  6. Median Freedom from Local Progression (FFLP) in phase 1 participants with recurrent GBM/GS [ Time Frame: Until study stops or death; up to approximately 3 years. ]

    FFLP defined as time from date of registration to the date of documented local progressive disease. Determined by mRANO criteria.

    This measure includes only phase 1 participants with recurrent GBM/GS.


  7. Median Overall Survival (OS) in phase 1 participants with recurrent GBM/GS [ Time Frame: Until study stops or death; up to approximately 3 years. ]

    OS defined as time from date of registration to date of death or last follow up. Determined by Kaplan Meier method.

    This measure includes only phase 1 participants with recurrent GBM/GS.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Glioblastoma or gliosarcoma (recurrent or newly diagnosed).
  • Karnofsky Performance Status 60 or greater.
  • Phase 0: Candidate for clinically indicated re-resection or biopsy of glioblastoma or gliosarcoma per treating physician(s).
  • Phase 1, Recurrent: Candidate for clinically indicated re-irradiation of glioblastoma or gliosarcoma per treating physician(s) (No more than one prior course of radiation for GBM).
  • Phase 1, Newly Diagnosed: Candidate for upfront standard of care chemoradiation for glioblastoma or gliosarcoma per treating physician(s), to start no earlier than 14 days post- operatively from last definitive surgery for glioblastoma or gliosarcoma (if more than one surgery done. Ex. biopsy prior to resection).
  • ANC >=1,500 cells/mm^3 within 14 days prior to enrollment.
  • Patient (men and childbearing age women) agrees to the use of highly effective contraception during study participation and for at least 6 weeks for female patients and 90 days for male patients after final MMF administration.
  • Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:

  • Lack of histopathological diagnosis of the tumor.
  • Gliomatosis cerebri pattern (tumor involving 3 or more lobes) of disease.
  • Leptomeningeal disease.
  • Use of bevacizumab within 8 weeks of study enrollment.
  • Known history of HIV.
  • Active hepatitis B or C infection.
  • Active systemic or central nervous system (CNS) infection.
  • Grade 4 lymphopenia (if ALC <0.5, patient must be on Pneumocystis jirovecii prophylaxis).
  • Estimated CrCl < 25 ml/min.
  • History of organ transplantation.
  • Patients with known hypoxanthine-guanine phosphoribosyl-transferase deficiency.
  • Serious intercurrent disease.
  • History of allergic reaction or hypersensitivity to mycophenolate mofetil or mycophenolic acid or any component of the drug product; or medical contraindication for MMF per treating physician(s).
  • Known immunosuppressive condition from autoimmune disease, immune deficiency syndrome, or chronic immunosuppressive therapy.
  • Inability to undergo MRI brain with and without contrast.
  • Pregnant or lactating women.
  • Patients with known phenylketonuria.
  • Phase 0: Patients undergoing biopsy who are deemed unlikely to have sufficient tissue to spare for research purposes (e.g., those whose tumors are in an eloquent brain location where all tissue taken must be used for diagnostic purposes).
  • Phase I: Increase in steroid requirement within 7 days of study enrollment (stable or decreasing dose allowed).
  • Phase I, Recurrent: Radiation within 6 months prior to study enrollment.
  • Phase I, Recurrent: Surgery within 4 weeks of re-irradiation.
  • Phase I, Newly Diagnosed: History of hypersensitivity reactions to temozolomide or any other ingredients in temozolomide and dacarbazine.
  • Phase I, Newly Diagnosed: Prior chemotherapy or radiation therapy for glioblastoma or gliosarcoma.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04477200


Locations
Layout table for location information
United States, Michigan
University of Michigan Rogel Cancer Center Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Cancer AnswerLine    800-865-1125    CancerAnswerLine@med.umich.edu   
Principal Investigator: Yoshie Umemura, M.D.         
Sponsors and Collaborators
University of Michigan Rogel Cancer Center
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Yoshie Umemura, MD University of Michigan Rogel Cancer Center
Layout table for additonal information
Responsible Party: University of Michigan Rogel Cancer Center
ClinicalTrials.gov Identifier: NCT04477200    
Other Study ID Numbers: UMCC 2019.192
HUM00175785 ( Other Identifier: University of Michigan )
R37CA258346 ( U.S. NIH Grant/Contract )
First Posted: July 20, 2020    Key Record Dates
Last Update Posted: January 26, 2022
Last Verified: January 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Glioblastoma
Gliosarcoma
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Mycophenolic Acid
Temozolomide
Antibiotics, Antineoplastic
Antineoplastic Agents
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Alkylating
Alkylating Agents